PCOVERY
Pcovery is a focused drug discovery company within the anti-fungal area. We combine our expertise within protein structure, medicinal chemistry, drug discovery and -development, and pathogenic fungal infections to create a novel class of anti-fungals to treat serious invasive fungal infections. Pcovery's research platform combines a number of powerful technologies to identify, evaluate and optimize novel antifungal compounds. We carry out high throughput in vitro and in vivo fungicidal activ... ity screens, specificity, synergy and resistance screenings, as well as structural characterization of drug-target interactions by X-ray crystallography. Our research team and advisors include specialists in anti-fungal drug development, chemistry, biochemistry, structural biology and membrane transport, providing us with a unique set of expertise to achieve our ambitious goal of developing a powerful novel type of anti-fungal drug.
PCOVERY
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2009-04-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.pcovery.com
Total Employee:
1+
Status:
Active
Contact:
(455) 159-4560
Email Addresses:
[email protected]
Technology used in webpage:
Google Font API Nginx Euro Google Maps GStatic Google Static Content Google Maps API
Current Advisors List
Official Site Inspections
http://www.pcovery.com
- Host name: 162.255.119.43
- IP address: 162.255.119.43
- Location: Los Angeles United States
- Latitude: 34.0318
- Longitude: -118.4252
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90064
More informations about "PCOVERY"
Pcovery Company Profile 2024: Valuation, Funding & Investors
Pcovery General Information Description. Developer of cardiovascular drugs intended to cure fungal infections and cardiovascular diseases. The company's cardiovascular drugs build compound that selectively shuts down an essential plasma membrane transport system in the fungi, enabling doctors to cure fungal infections faster.See details»
Pcovery Management Team | Org Chart - RocketReach
Pcovery focuses on the development of a new antifungal drug. The approach is to use structure based drug discovery on membrane protein drug targets.See details»
Xcovery
At Xcovery, our mission is simple: to employ advanced science to create leading-edge oncology therapies that are not only more effective than current options but are also less toxic and more tolerable for those who need them. Read More . Ensartinib: Potentially the best-in …See details»
Pcovery - VentureRadar
Jan 8, 2017 "Pcovery focus on developing new drugs for treatment of invasive fungal infections. Pcovery aims to develop a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane.See details»
Pcovery (company) | Nordic 9
Pcovery (company). Pcovery is a focused drug discovery company within the anti-fungal area. We combine our expertise within protein structure, medicinal chemistry, drug discovery and -development, and pathogenic fungal infections to create a novel class of anti-fungals to treat serious invasive fungal infections. Pcovery's research platform combines a number of powerful …See details»
About Us - Xcovery
Xcovery was represented at the WCLC 2024 in San Diego with new data on ensartinib activity in ALK or MET positive NSCLC and the dose escalation results of MRX-2843 in NSCLC. Giovanni Selvaggi M.D., Xcovery’s CMO attended the conference. Betta pharmaceutical mini oral presentation on ensartinib as MET inhibitor MA06.11See details»
Xcovery Holding, Inc. - Drug pipelines, Patents, Clinical trials
He is currently Chief Medical Officer at Xcovery Holdings, where he manages an ongoing New Drug Application with the FDA for ensartinib, an ALK-TKI for non-small cell lung cancer (NSCLC). ... The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into ...See details»
Pcovery - Products, Competitors, Financials, Employees, …
Pcovery is a provider in structure based drug development against membrane protein drug targets with a broad portfolio of innovative technologies, drug targets and chemical products. Use the CB Insights Platform to explore Pcovery's full profile.See details»
Xcovery - Crunchbase Company Profile & Funding
Xcovery’s Vice President, Oncology, Dr. Jay Gibbons, brings more than 25 years of oncology research and management experience to the team with a strong emphasis on translational medicine. During his previous role as AVP, Oncology Research at Wyeth, he was instrumental in filing eight IND’s and the NDA for Torisel® (temsirolimus), currently approved for the treatment …See details»
Xcovery, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
From March 2019, Dr. Selvaggi has been the Chief Medical Officer at Xcovery. About Xcovery Xcovery is a biopharmaceutical company working to improve the lives of patients with cancer by discovering medicines to fight advanced tumors. Xcovery is developing a pipeline of oncology therapies to target a wide range of advanced tumors.See details»
Tyrogenex - Crunchbase Company Profile & Funding
The company has developed a novel, patented cancer therapeutic, X-82, a dual VEGFR/PDGFR inhibitor. The company was formerly known as Xcovery, Inc. The company was incorporated in 2006 and is. based in West Palm Beach, Florida. The company operates as …See details»
Xcovery Company Profile 2024: Valuation, Funding & Investors
Xcovery General Information Description. Developer of novel therapies intended to build a pipeline of oncology medicines for advanced malignant tumors. The company's small-molecule targeted oncology therapies eliminate the challenges associated with cancer treatment resistance, enabling patients to receive painless treatments.See details»
Xcovery Company Profile - Office Locations, Competitors ... - Craft
Xcovery a biopharmaceutical company discovering and developing medicines to fight advanced tumors. It works on a pipeline of oncology therapies to target a range of malignant diseases. It develops a product, ensartinib (X-396), a small molecule that …See details»
U.S. Food and Drug Administration (FDA) Has Accepted the New …
MIAMI, March 13, 2024--Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application ...See details»
Xcovery Holdings - VentureRadar
Xcovery Vision is an ophthalmology-focused subsidiary of Xcovery Holdings, a clinical-stage company developing novel therapies for cancer and inflammatory diseases. Xcovery Vision's goal is to develop innovative therapies to address unmet healthcare needs and improve the standard of care in the field of ophthalmology.See details»
ENSACOVE, A World Intellectual Property Organization Trademark …
ENSACOVE is a WIPO trademark and brand of Xcovery Holdings, Inc., 11780 US HWY 1, Suite 202, Palm Beach Gardens FL 33408,UNITED STATES. This trademark was filed to WIPO on Wednesday, October 30, 2019. The ENSACOVE is under the trademark classification: Pharmaceutical Products; The ENSACOVE trademark covers Therapeutic pharmaceuticals …See details»
Xcovery Announces the Appointment of Giovanni Selvaggi as …
Mar 18, 2021 PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Mar 18, 2021-- Xcovery Holdings, Inc., an oncology focused bio-pharmaceutical company, today announced that Giovanni Selvaggi, M.D., has been appointed as the Chief Executive Officer (CEO), replacing Li Mao, M.D., who is leaving for personal reasons. Dr. Selvaggi will also continue as Xcovery’s Chief Medical …See details»
Xcovery - Contacts, Employees, Board Members, Advisors & Alumni
Xcovery has 5 current employee profiles, including C.F.A., Vice President of Business and Corporate Development Fred Meyer. Fred Meyer C.F.A., Vice President of Business and Corporate Development Jay Gibbons Vice President, OncologySee details»
For Patients - Xcovery
Xcovery has developed a portfolio of low toxicity kinase inhibitors, which may allow for different therapies to address important hallmarks of cancer. ... This organization’s aim is to triple the number of lung cancer survivors over the next decade through advancing research, enhancing access to quality care, and framing the conversation. ...See details»
Xcovery - Overview, News & Similar companies | ZoomInfo.com
May 23, 2022 Xcovery SHP2 Inhibitor IND Approved by US FDA PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Xcovery Holdings, Inc., an oncology focused bio-pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational New Drug application (IND) of BPI-442096 , a small molecule Src homology …See details»